Oncotype DX breast cancer assay
Term · Oncology and biomedicine · MLC-T-ONC-006078
A lab test that is used to help predict whether breast cancer will come back or spread to other parts of the body. The test looks at the activity level of 21 different genes in breast cancer tissue of people with early-stage (stage I, II, or IIIA) invasive breast cancer that is estrogen receptor (ER) positive, HER2 negative, and is either node-negative or has spread to 1 to 3 lymph nodes. If the test shows that there is a high risk that the cancer will spread or come back, treatment with chemotherapy may be needed to lower the risk. Also called 21-gene signature.
| Identifier | MLC-T-ONC-006078 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | 21-gene signature |
| References | NCI Dictionary of Cancer Terms |
| See also | Oncotype DX ductal carcinoma in situ (DCIS) assay |
Record as JSON
{
"id": "MLC-T-ONC-006078",
"term": "Oncotype DX breast cancer assay",
"field": "Oncology and biomedicine",
"definition": "A lab test that is used to help predict whether breast cancer will come back or spread to other parts of the body. The test looks at the activity level of 21 different genes in breast cancer tissue of people with early-stage (stage I, II, or IIIA) invasive breast cancer that is estrogen receptor (ER) positive, HER2 negative, and is either node-negative or has spread to 1 to 3 lymph nodes. If the test shows that there is a high risk that the cancer will spread or come back, treatment with chemotherapy may be needed to lower the risk. Also called 21-gene signature.",
"synonyms": [
"21-gene signature"
],
"see_also": [
"Oncotype DX ductal carcinoma in situ (DCIS) assay"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/oncotype-dx-breast-cancer-assay/"
}
Record 12,233 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.